Man Group plc Sells 18,921 Shares of DaVita Inc. (NYSE:DVA)

Man Group plc reduced its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 64.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,260 shares of the company's stock after selling 18,921 shares during the period. Man Group plc's holdings in DaVita were worth $1,534,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of DVA. SBI Securities Co. Ltd. acquired a new position in DaVita in the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC lifted its holdings in DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares during the period. Canada Post Corp Registered Pension Plan bought a new stake in DaVita in the fourth quarter valued at approximately $55,000. Venturi Wealth Management LLC increased its stake in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after purchasing an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on DVA. Truist Financial lowered their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Stock Down 0.4%

Shares of DVA stock traded down $0.57 during trading hours on Thursday, hitting $136.10. 284,948 shares of the company were exchanged, compared to its average volume of 870,846. The business has a 50 day moving average of $144.67 and a two-hundred day moving average of $153.13. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60. The company has a market capitalization of $10.28 billion, a PE ratio of 12.67, a PEG ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.26 earnings per share. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.